• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

F12 作为一种与甲状腺乳头状癌免疫浸润相关的可靠诊断和预后生物标志物。

F12 as a reliable diagnostic and prognostic biomarker associated with immune infiltration in papillary thyroid cancer.

机构信息

Department of Thyroid and Breast Surgery, Linping Campus, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 311100, Zhejiang, China.

Department of Thyroid Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China.

出版信息

Aging (Albany NY). 2022 Apr 28;14(8):3687-3704. doi: 10.18632/aging.204037.

DOI:10.18632/aging.204037
PMID:35483340
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9085229/
Abstract

OBJECTIVE

To explore the function of coagulation factor XII (F12) in papillary thyroid cancer (PTC).

MATERIALS AND METHODS

We assessed F12 expression and its relationship with overall survival (OS) in various cancers using TIMER and TISIDB databases. Further, we evaluated the mRNA and protein expression levels of F12 in PTC via different bioinformatics tools. The receiver operating characteristic (ROC) curve was applied to determine the diagnostic value of F12 in PTC. Then, the Kaplan-Meier plotter and Cox regression analyses were performed to examine the prognostic significance of F12. The possible mechanism of F12 in PTC was investigated through enrichment analyses. Finally, the correlation between F12 expression and immune cell infiltration was analyzed using TCGA data.

RESULTS

This study revealed the clinical significance of F12 in various cancers. Higher mRNA (P <0.001) and protein expressions of F12 were observed in PTC compared with normal tissues. Besides, F12 expression exhibited high diagnostic performance in PTC and its overexpression served as an independent predictor for the poor OS (P <0.05). Enrichment analyses results showed that F12 was mainly involved in metabolism-associated pathways. Additionally, F12 expression was significantly linked to immune cell infiltration levels, especially macrophage infiltration.

CONCLUSIONS

F12 might be a reliable diagnostic and prognostic biomarker for PTC. Moreover, F12 expression might affect the OS of PTC patients via regulating metabolic pathways.

摘要

目的

探索凝血因子 XII（F12）在甲状腺乳头状癌（PTC）中的作用。

材料与方法

我们使用 TIMER 和 TISIDB 数据库评估了 F12 在各种癌症中的表达及其与总生存期（OS）的关系。此外，我们通过不同的生物信息学工具评估了 F12 在 PTC 中的 mRNA 和蛋白表达水平。采用受试者工作特征（ROC）曲线来确定 F12 在 PTC 中的诊断价值。然后，通过 Kaplan-Meier 绘图器和 Cox 回归分析来检验 F12 的预后意义。通过富集分析研究了 F12 在 PTC 中的可能机制。最后，使用 TCGA 数据分析了 F12 表达与免疫细胞浸润的相关性。

结果

本研究揭示了 F12 在各种癌症中的临床意义。与正常组织相比，PTC 中 F12 的 mRNA（P<0.001）和蛋白表达水平更高。此外，F12 表达在 PTC 中具有较高的诊断性能，其过表达是 OS 不良的独立预测因子（P<0.05）。富集分析结果表明，F12 主要参与代谢相关途径。此外，F12 表达与免疫细胞浸润水平显著相关，特别是巨噬细胞浸润。

结论

F12 可能是 PTC 可靠的诊断和预后生物标志物。此外，F12 表达可能通过调节代谢途径影响 PTC 患者的 OS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/35a09954daad/aging-14-204037-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/f76fd534082a/aging-14-204037-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/6175f0f5e181/aging-14-204037-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/2fbbcf3ac1a8/aging-14-204037-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/68c22ddda04c/aging-14-204037-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/46c368d3466d/aging-14-204037-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/a86a520805dd/aging-14-204037-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/6e3c7630f4be/aging-14-204037-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/bdd35ac96ef1/aging-14-204037-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/7d2f702b1d3a/aging-14-204037-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/36ee43108f20/aging-14-204037-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/35a09954daad/aging-14-204037-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/f76fd534082a/aging-14-204037-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/6175f0f5e181/aging-14-204037-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/2fbbcf3ac1a8/aging-14-204037-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/68c22ddda04c/aging-14-204037-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/46c368d3466d/aging-14-204037-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/a86a520805dd/aging-14-204037-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/6e3c7630f4be/aging-14-204037-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/bdd35ac96ef1/aging-14-204037-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/7d2f702b1d3a/aging-14-204037-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/36ee43108f20/aging-14-204037-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/9085229/35a09954daad/aging-14-204037-g011.jpg

相似文献

1
F12 as a reliable diagnostic and prognostic biomarker associated with immune infiltration in papillary thyroid cancer.F12 作为一种与甲状腺乳头状癌免疫浸润相关的可靠诊断和预后生物标志物。
Aging (Albany NY). 2022 Apr 28;14(8):3687-3704. doi: 10.18632/aging.204037.
2
OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer.OGDHL 与肿瘤微环境密切相关，可作为甲状腺乳头状癌的预后生物标志物。
Cancer Med. 2021 Jan;10(2):728-736. doi: 10.1002/cam4.3640. Epub 2021 Jan 6.
3
TET1 is a Diagnostic and Prognostic Biomarker Associated with Immune Infiltration in Papillary Thyroid Cancer.TET1 是与甲状腺乳头状癌免疫浸润相关的诊断和预后生物标志物。
Biochem Genet. 2024 Apr;62(2):718-740. doi: 10.1007/s10528-023-10442-5. Epub 2023 Jul 6.
4
A Potential Nine-lncRNAs Signature Identification and Nomogram Diagnostic Model Establishment for Papillary Thyroid Cancer.潜在的九长链非编码 RNA 标志物鉴定和列线图诊断模型在甲状腺乳头状癌中的建立。
Pathol Oncol Res. 2022 Feb 23;28:1610012. doi: 10.3389/pore.2022.1610012. eCollection 2022.
5
[Bioinformatic analysis of CCND2 expression in papillary thyroid carcinoma and its impact on immune infiltration].[甲状腺乳头状癌中CCND2表达的生物信息学分析及其对免疫浸润的影响]
Nan Fang Yi Ke Da Xue Xue Bao. 2024 May 20;44(5):981-988. doi: 10.12122/j.issn.1673-4254.2024.05.21.
6
Identification of lipid metabolism-related genes as prognostic indicators in papillary thyroid cancer.鉴定脂质代谢相关基因作为甲状腺乳头状癌的预后指标。
Acta Biochim Biophys Sin (Shanghai). 2021 Dec 8;53(12):1579-1589. doi: 10.1093/abbs/gmab145.
7
Analysis of the Prognostic Value and Potential Molecular Mechanisms of TREM-1 Overexpression in Papillary Thyroid Cancer Bioinformatics Methods.甲状腺乳头状癌中 TREM-1 过表达的预后价值及潜在分子机制分析 生物信息学方法。
Front Endocrinol (Lausanne). 2021 May 27;12:646793. doi: 10.3389/fendo.2021.646793. eCollection 2021.
8
Biomarkers related to m6A and succinic acid metabolism in papillary thyroid carcinoma.甲状腺乳头状癌中与m6A和琥珀酸代谢相关的生物标志物。
BMC Med Genomics. 2024 Aug 7;17(1):199. doi: 10.1186/s12920-024-01975-8.
9
Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.利用网络分析鉴定甲状腺乳头状癌免疫浸润和预后中的铁死亡基因
BMC Genomics. 2021 Jul 27;22(1):576. doi: 10.1186/s12864-021-07895-6.
10
Genome-wide scanning for CHD1L gene in papillary thyroid carcinoma complicated with type 2 diabetes mellitus.甲状腺乳头状癌合并2型糖尿病中CHD1L基因的全基因组扫描
Clin Transl Oncol. 2021 Dec;23(12):2536-2547. doi: 10.1007/s12094-021-02656-z. Epub 2021 Jul 10.

引用本文的文献

1
Coagulation-related genes for thyroid cancer prognosis, immune infltration, staging, and drug sensitivity.甲状腺癌预后、免疫浸润、分期和药物敏感性的相关凝血基因。
Front Immunol. 2024 Oct 21;15:1462755. doi: 10.3389/fimmu.2024.1462755. eCollection 2024.
2
A Novel Neutrophil Extracellular Trap Signature Predicts Patient Chemotherapy Resistance and Prognosis in Lung Adenocarcinoma.一种新型中性粒细胞胞外陷阱特征可预测肺腺癌患者的化疗耐药性和预后。
Mol Biotechnol. 2025 May;67(5):1939-1957. doi: 10.1007/s12033-024-01170-1. Epub 2024 May 11.
3
Identification of Serum Biomarkers to Monitor Therapeutic Response in Intestinal-Type Gastric Cancer.

本文引用的文献

1
Small extracellular vesicles containing miR-30a-3p attenuate the migration and invasion of hepatocellular carcinoma by targeting SNAP23 gene.含有 miR-30a-3p 的小细胞外囊泡通过靶向 SNAP23 基因抑制肝癌细胞的迁移和侵袭。
Oncogene. 2021 Jan;40(2):233-245. doi: 10.1038/s41388-020-01521-7. Epub 2020 Oct 27.
2
A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma.免疫相关基因对的特征可预测肺腺癌的肿瘤学结局和免疫治疗反应。
Genomics. 2020 Nov;112(6):4675-4683. doi: 10.1016/j.ygeno.2020.08.014. Epub 2020 Aug 13.
3
Global Burden of Thyroid Cancer From 1990 to 2017.
鉴定血清生物标志物以监测肠型胃癌的治疗反应。
Int J Mol Sci. 2024 Mar 8;25(6):3129. doi: 10.3390/ijms25063129.
4
Value of circulating neutrophil elastase for detecting recurrence of differentiated thyroid cancer.循环中性粒细胞弹性蛋白酶在检测分化型甲状腺癌复发中的价值。
Endocr Connect. 2023 Nov 20;12(12). doi: 10.1530/EC-23-0400. Print 2023 Dec 1.
5
Clinical significance of matrix metalloproteinase-9 expression in papillary thyroid carcinoma: a meta-analysis.基质金属蛋白酶-9 在甲状腺乳头状癌中的表达的临床意义：一项荟萃分析。
World J Surg Oncol. 2023 Jul 26;21(1):225. doi: 10.1186/s12957-023-03101-x.
全球 1990 年至 2017 年甲状腺癌负担研究
JAMA Netw Open. 2020 Jun 1;3(6):e208759. doi: 10.1001/jamanetworkopen.2020.8759.
4
Guidelines and definitions for research on epithelial-mesenchymal transition.上皮-间质转化研究的指南和定义。
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352. doi: 10.1038/s41580-020-0237-9. Epub 2020 Apr 16.
5
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
6
Macrophages and Metabolism in the Tumor Microenvironment.肿瘤微环境中的巨噬细胞和代谢
Cell Metab. 2019 Jul 2;30(1):36-50. doi: 10.1016/j.cmet.2019.06.001.
7
gene expression independently predicts favorable recurrence-free survival of classical papillary thyroid cancer.基因表达独立预测经典型甲状腺乳头状癌有利的无复发生存。
Future Oncol. 2019 Apr;15(12):1303-1311. doi: 10.2217/fon-2018-0885. Epub 2019 Feb 13.
8
Therapeutic strategies to target RAS-mutant cancers.靶向 RAS 突变型癌症的治疗策略。
Nat Rev Clin Oncol. 2018 Nov;15(11):709-720. doi: 10.1038/s41571-018-0105-0.
9
Novel potential inhibitors of complement system and their roles in complement regulation and beyond.新型补体系统潜在抑制剂及其在补体调节中的作用及其他。
Mol Immunol. 2018 Oct;102:73-83. doi: 10.1016/j.molimm.2018.05.023. Epub 2018 Jun 7.
10
M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors.M1 巨噬细胞衍生的纳米囊泡增强免疫检查点抑制剂的抗癌疗效。
ACS Nano. 2018 Sep 25;12(9):8977-8993. doi: 10.1021/acsnano.8b02446. Epub 2018 Aug 29.